drugset / Trial / NCT05416762
Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
RandomizedCrossoverOpen-labelTreatment
Summary
An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.
Timeline
- Start
- 2022-09-19
- Primary completion
- 2022-11-25
- Completion
- 2022-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vortioxetine | Unknown | 5 mg | Oral |
| Subject | Vortioxetine | Unknown | 10 mg | Oral |
| Subject | Vortioxetine | Unknown | 20 mg | Oral |